Bone sarcoma incidence in the Netherlands

AimsChondrosarcoma, osteosarcoma and Ewing sarcoma form the majority of malignant primary tumours of bone. High-grade bone sarcomas require intensive treatment due to their rapid and invasive growth pattern and metastasising capabilities. This nationwide study covers overall incidence, treatment and survival patterns of bone sarcomas in a 15-year period (2000–2014) in the total population of the Netherlands.Patients and methodsData for this study were derived from the Netherlands Cancer Registry, which receives primary notification from the national pathology database. Classification and categorisation was based on the ICD-O-3 classification and the WHO classification 2013 applied according to our clinicopathological expertise. Overall incidence over the 15-year-period was calculated as a rate per 100,000 person-years (using the European Standardised Rate, ESR). Survival was analysed with Kaplan-Meier curves and Cox proportional hazards regression.ResultsIncidence for high-grade chondrosarcoma (n = 429) was estimated at 0.15 per 100,000 ESR, and 5-year overall survival at 65.9% (95% confidence interval (CI): 61.0%–70.4%). Incidence for high-grade central osteosarcoma (n = 605) was estimated at 0.25 per 100,000 ESR and 5-year survival at 53.9% (95%CI: 49.7%–58.0%). Ewing sarcoma incidence (n = 334) was estimated at 0.15 per 100,000 ESR and 5-year survival at 59.3% (95%CI: 53.5%–64.6%). For high-grade central osteosarcoma, treatment at a bone tumour centre was associated with better survival (HR 0.593).ConclusionsThis study provides comprehensive incidence estimates for all the main primary bone sarcomas over a 15-year time period in a Northern European country with little migration. Centralisation of bone sarcoma care improves the clinical outcome in osteosarcoma.     

Type IIB Procollagen NH2-propeptide Induces Death of Tumor Cells via Interaction with Integrins αVβ3 and αVβ5

Cartilage is resistant to tumor invasion. In the present study, we found that the NH₂-propeptide of the cartilage-characteristic collagen, type IIB, PIIBNP, is capable of killing tumor cells. The NH₂-propeptide is liberated into the extracellular matrix prior to deposition of the collagen fibrils. This peptide adheres to and kills cells from chondrosarcoma and cervical and breast cancer cell lines via the integrins α_vβ₅ and α_vβ₃. Adhesion is abrogated by blocking with anti α_vβ₅ and α_vβ₃ antibodies. When α_v is suppressed by small intefering RNA, adhesion and cell killing are blocked. Normal chondrocytes from developing cartilage do not express α_vβ₃ and α_vβ₅ integrins and are thus protected from cell death. Morphological, DNA, and biochemical evidence indicates that the cell death is not by apoptosis but probably by necrosis. In an assay for invasion, PIIBNP reduced the number of cells crossing the membrane. In vivo, in a tumor model for breast cancer, PIIBNP was consistently able to reduce the size of the tumor.     

Fascin蛋白在软骨肉瘤中的表达及其临床意义

目的：分析Fascin蛋白在软骨肉瘤组织中的表达及其与软骨肉瘤临床病理因素的关系。方法：应用免疫组化EnlivionTM法分别检测和比较70例软骨肉瘤和20例软骨瘤中Fascin蛋白的表达情况。结果：（1）Fascin在软骨肉瘤组和软骨瘤组中的阳性表达率分别为64．29％和5．00％,两组相比差异有统计学意义（X2=21．88,P=0．00）;（2）Fascin蛋白的表达与患者的年龄、性别无显著相关性（Xk0．37,P=0．54;X2=-0．29,P=0．59）;Fascin蛋白在肺转移组中的表达为76．32％,显著高于无肺转移组（50．00％）,两组相比差异有统计学意义（XZ=5．24,P=0．02）;Fascin蛋白在间叶性软骨肉瘤、透明细胞软骨肉瘤的中表达分别与普通型软骨肉瘤相比,无统计学意义（P〉0．05）,但去分化软骨肉瘤与普通型软骨肉瘤相比,有统计学意义（P〈0．05）;Fascin在普通型软骨肉瘤的I-III级中的阳性表达率分别为11．1l％、61．90％、75．00％,三者之间的差异有统计学意义（P〈0．05）。结论：Fascin参与了软骨肉瘤恶变的过程,其高表达与软骨肉瘤的分化和转移有关。     

Notch通路与基质金属蛋白酶在软骨肉瘤中的表达及意义

目的 研究软骨肉瘤组织中Notch通路、p38丝裂原活化蛋白激酶(MAPK)及基质金属蛋白酶(MMPs)的表达情况,探讨它们在软骨肉瘤间质浸润中的作用机制.方法 收集正常软骨组织标本10例、内生性软骨瘤标本23例和软骨肉瘤标本32例,分别用免疫组化、Western blot和real-time PCR检测Notch1、Jagged1、MMP-1、MMP-13、p38 MAPK及p-p38 MAPK的表达情况.结果 与正常软骨组织相比,Notch1、Jagged1、MMP-1、MMP-13及p-p38 MAPK在内生性软骨瘤表达部分升高,在软骨肉瘤表达均明显增加(P＜0.01).p38 MAPK在正常软骨组织、内生性软骨瘤及软骨肉瘤组织中表达无明显差异(P＞0.05).结论 Notch通路和p38 MAPK通过调节基质金属蛋白酶在软骨肉瘤中的表达,来增加软骨肉瘤的浸润转移能力.     

Intrinsic radiation resistance in human chondrosarcoma cells

Human chondrosarcomas rarely respond to radiation treatment, limiting the options for eradication of these tumors. The basis of radiation resistance in chondrosarcomas remains obscure. In normal cells radiation induces DNA damage that leads to growth arrest or death. However, cells that lack cell cycle control mechanisms needed for these responses show intrinsic radiation resistance. In previous work, we identified immortalized human chondrosarcoma cell lines that lacked p16(ink4a), one of the major tumor suppressor proteins that regulate the cell cycle. We hypothesized that the absence of p16(ink4a) contributes to the intrinsic radiation resistance of chondrosarcomas and that restoring p16(ink4a) expression would increase their radiation sensitivity. To test this we determined the effects of ectopic p16(ink4a) expression on chondrosarcoma cell resistance to low-dose gamma-irradiation (1-5 Gy). p16(ink4a) expression significantly increased radiation sensitivity in clonogenic assays. Apoptosis did not increase significantly with radiation and was unaffected by p16(ink4a) transduction of chondrosarcoma cells, indicating that mitotic catastrophe, rather than programmed cell death, was the predominant radiation effect. These results support the hypothesis that p16(ink4a) plays a role in the radiation resistance of chondrosarcoma cell lines and suggests that restoring p16 expression will improve the radiation sensitivity of human chondrosarcomas.     

IL-8 increases integrin expression and cell motility in human chondrosarcoma cells

Chondrosarcoma is a type of highly malignant tumor with a potent capacity to invade locally and cause distant metastasis. Chondrosarcoma shows a predilection for metastasis to the lungs. Interleukin-8 (IL-8), a chemokine with a defining CXC amino acid motif, is known to possess tumorigenic and proangiogenic properties. Over-expression of IL-8 has been detected in many human tumors. However, the effects of IL-8 in migration and integrin expression in chondrosarcoma cells are largely unknown. In this study, we found that IL-8 increased the migration and the expression of αvβ3 integrin in human chondrosarcoma cells. Activations of phosphatidylinositol 3-kinase (PI3K), Akt, and AP-1 pathways after IL-8 treatment were demonstrated, and IL-8-induced expression of integrin and migration activity was inhibited by the specific inhibitor and mutant of PI3K, Akt, and AP-1 cascades. Taken together, our results indicated that IL-8 enhances the migration of chondrosarcoma cells by increasing αvβ3 integrin expression through the PI3K/Akt/AP-1 signal transduction pathway.     

Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21

We previously reported that 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), the most potent agonist for peroxisome proliferator-activated receptor gamma (PPAR gamma), induces apoptosis of human chondrosarcoma cell line OUMS-27. The current study aimed to explore the mechanism of 15d-PGJ(2)-induced apoptosis and inhibition of cell proliferation in OUMS-27 cells. The preliminary results of cDNA microarray analysis showed the down-regulation of anti-apoptotic Bcl-xL and up-regulation of pro-apoptotic Bax in the process of 15d-PGJ(2)-induced apoptosis. These changes were further confirmed at mRNA and protein levels by RT-PCR and Western blot analysis, respectively. Among cyclin-dependent kinase inhibitors, p21 was induced and up-regulated by 15d-PGJ(2), but p16 and p27 were not changed, suggesting that the involvement of p21 in inhibition of cell proliferation. Activation of caspase-3 by 15d-PGJ(2) was partly, but not completely, blocked by PPAR gamma antagonist (GW9662) suggesting the 15d-PGJ(2) exerted its effect by PPAR gamma-dependent and -independent pathways. Interestingly, immunohistochemical study on human chondrosarcoma samples revealed that Bcl-xL is frequently expressed by tumor cells. The results of the current study suggest that the potential ability of 15d-PGJ(2) in regulation of cell cycle and inhibition of Bcl-xL expression might be beneficial in the development of novel pharmacological agents for chondrosarcoma.     

Identification of medicinal compounds as potential inhibitors for mutated isocitrate dehydrogenases against chondrosarcoma

Chondrosarcoma is the third most common cartilaginous bone tumour that is insusceptible to radio- and chemotherapy and it is inclined to metastasis. These resistant qualities are facilitated by mutant variants of isocitrate dehydrogenases (IDH) 1–2 enzyme. These mutant enzymes promote oncogenesis of chondrocytes by changing their epigenetic wardrobe leading to tumour formation. Presently, there are lack of drugs available to be exploited as a remedy for this disease. On the other hand, majority of chemotherapeutic drugs induce cytotoxicity in the cancer cells at the cost of harming surrounding healthy cells, jeopardizing human life. The current study is focused on screening various medicinal compounds against IDH1 and IDH2 combined with insilico gene expression, cancer cells cytotoxicity and ADMET (absorption, distribution, metabolism, excretion and toxicity) studies to elucidate the molecular mechanism against chondrosarcoma and also to uncover pharmacokinetic profile of these compounds. Screening of 5000+ compounds filtered two efficacious compounds (Artocarpetin and 5-Galloylquinic acid) capable of establishing hydrogen bond connections with both IDH variants. Other studies showed that these compounds downregulate ITGAV, CARPIN1, CCL5 and COG5 and TNFRSF10B gene that reduces chondrogenesis and inflammation, Artocarpetin and 5-galloylquinic acid are TP53 expression enhancer and inhibit MM9 expression that promote immunomodulation and apoptosis in these cancers. These compounds are both active against CHSA8926 and CHSA011 cell line of chondrosarcoma. However, the ADME profile of 5-galloylquinic acid is slightly unsatisfactory based on druglikness and bioavailability score criteria as compared to artocarpetin. Both of these compounds are class-5 chemicals and require high doses to elicit adverse response. Our results suggest that artocarpetin and 5-galloylquinic acid are efficacious drug candidates and could be further exploited to validate these findings in vitro.     

Anti-chondrosarcoma effects of PEDF mediated via molecules important to apoptosis, cell cycling, adhesion and invasion

Chondrosarcoma develops as a result of overgrowth of chondrocytes and overproduction of cartilage matrix. It is currently surgically treated, although non-invasive methods are being sought. In this report, pigment epithelium-derived factor (PEDF) induced apoptosis in the chondrosarcoma cell line - JJ012, with upregulation of Bax, Fas, caspase-3 and -6 and downregulation of Bcl-2. Cell cycling was also decreased with decreased expression of p38, p-Akt, p-Erk and JNK1 and increased expression of p73 and E2F1. Furthermore, PEDF increased adhesion of cells to collagen-I, with decreased expression of p-Fak, RhoA and cdc42. Invasion of cells through collagen-I was also reduced by PEDF, with decreased expression of uPAR, MMP-14 and increased expression of PAI-1. These findings seminally indicate that PEDF may have potential as an anti-cancer agent against chondrosarcoma.     

Fascin 蛋白在软骨肉瘤中的表达及其临床意义

目的：分析Fascin 蛋白在软骨肉瘤组织中的表达及其与软骨肉瘤临床病理因素的关系。方法：应用免疫组化EnlivionTM 法 分别检测和比较70 例软骨肉瘤和20 例软骨瘤中Fascin 蛋白的表达情况。结果：(1) Fascin 在软骨肉瘤组和软骨瘤组中的阳性表 达率分别为64.29%和5.00%,两组相比差异有统计学意义(X2= 21.88,P=0.00);(2)Fascin 蛋白的表达与患者的年龄、性别无显著相 关性(X2= 0.37,P=0.54;X2=0.29,P=0.59);Fascin 蛋白在肺转移组中的表达为76.32%,显著高于无肺转移组(50.00%),两组相比差 异有统计学意义(X2=5.24,P=0.02);Fascin 蛋白在间叶性软骨肉瘤、透明细胞软骨肉瘤的中表达分别与普通型软骨肉瘤相比,无统 计学意义(P>0.05),但去分化软骨肉瘤与普通型软骨肉瘤相比,有统计学意义(P<0.05);Fascin 在普通型软骨肉瘤的Ⅰ-Ⅲ级中的阳 性表达率分别为11.11%、61.90%、75.00%,三者之间的差异有统计学意义(P<0.05)。结论：Fascin 参与了软骨肉瘤恶变的过程,其高 表达与软骨肉瘤的分化和转移有关。